检索结果-南通市图书馆

Metastatic lymph nodes and prognosis assessed by the number of retrieved lymph nodes in gastric cancer

World Journal of Gastrointestinal Surgery 2022年第11期14卷 1230-1249页

作者： Hao wang xin Yin Sheng-Han Lou tian-Yi Fang Bang-Ling Han Jia-Liang Gao Yu-Fei wang Dao-Xu Zhang xi-Bo wang Zhan-Fei Lu Jun-Peng wu Jia-Qi Zhang Yi-min wang Yao Zhang Ying-wei Xue Department of Gastroenterological Surgery Harbin Medical University Cancer HospitalHarbin Medical University Cancer HospitalHarbin 150081Heilongjiang ProvinceChina

BACKGROUND The prognostic value of quantitative assessments of the number of retrieved lymph nodes(RLNs)in gastric cancer(GC)patients needs further *** To discuss how to obtain a more accurate count of metastatic lymph nodes(MLNs)based on RLNs in different pT stages and then to evaluate patient *** This study retrospectively analyzed patients who underwent GC radical surgery and D2/D2+LN dissection at the Cancer Hospital of Harbin Medical University from January 2011 to May *** weighted smoothing was used to analyze the relationship between RLNs and the number of *** cubic splines were used to analyze the relationship between RLNs and hazard ratios(HRs),and X-tile was used to determine the optimal cutoff value for *** survival was analyzed with the Kaplan-Meier method and log-rank ***,HRs and 95%confidence intervals were calculated using Cox proportional hazards models to analyze independent risk factors associated with patient *** A total of 4968 patients were included in the training cohort,and 11154 patients were included in the validation *** smooth curve showed that the number of MLNs increased with an increasing number of RLNs,and a nonlinear relationship between RLNs and HRs was observed.X-tile analysis showed that the optimal number of RLNs for pT1-pT4 stage GC patients was 26,31,39,and 45,respectively.A greater number of RLNs can reduce the risk of death in patients with pT1,pT2,and pT4 stage cancers but may not reduce the risk of death in patients with pT3 stage *** analysis showed that RLNs were an independent risk factor associated with the prognosis of patients with pT1-pT4 stage cancer(P=0.044,P=0.037,P=0.003,P<0.001).CONCLUSION A greater number of RLNs may not benefit the survival of patients with pT3 stage disease but can benefit the survival of patients with pT1,pT2,and pT4 stage *** the pT1,pT2,and pT4 stages,it is recommended to retrieve 26,31 an

关键词： Gastric cancer Metastatic lymph nodes Number of retrieved lymph nodes Prognosis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Photoluminescence of Polycrystalline SiC Sintered from Graphite and Si Melt

引用

Chinese Physics Letters 2000年第10期17卷 770-772页

作者： CHEN zhi-ming MA Jian-Ping wang Jian-Nong LU Gang YU ming-Bin LEI tian-min GE wei-Kun Department of Applied Electronics Xi'an University of TechnologyXi'an 710048 Department of Physics Hong Kong University of Sciences and TechnologyHong Kong

Intense wide-band photoluminescence(PL)with high stability to ultraviolet(UV)light irradiation has been observed in a wide temperature range from a polycrystalline SiC sintered from graphite and melt Si at high temperature over 1500°C.X-ray diffraction results showed that the sintered material consists of mainly cubic and 6H-SiC crystallites oriented randomly and a smallamount of graphite with(002)preferential *** of the samples were measured under excitation of the incident UV light beam from an He-Cd laser(325 nm,l0mW)in the temperature range from 10 to 300 *** PL spectra were found to be a single wide-band centered around 2.2 eV at room temperature and to be divided into a much more intensive blue band and a lessintensive red band at low *** low temperature PL bands consist of several luminescence peaks that change in intensities relatively with variation of temperature.

关键词： excitation ultraviolet cubic

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Back-n white neutron source at CSNS and its applications

引用

Nuclear Science and Techniques 2021年第1期32卷 95-104页

作者： Jing-Yu Tang Qi An Jiang-Bo Bai Jie Bao Yu Bao Ping Cao Hao-Lei Chen Qi-Ping Chen Yong-Hao Chen Zhen Chen Zeng-Qi Cui Rui-Rui Fan Chang-Qing Feng Ke-Qing Gao xiao-Long Gao min-Hao Gu Chang-Cai Han Zi-Jie Han Guo-Zhu He Yong-Cheng He yang Hong Yi-wei Hu Han-xiong Huang xi-Ru Huang Hao-Yu Jiang wei Jiang zhi-Jie Jiang Han-Tao Jing Ling Kang Bo Li Chao Li Jia-Wen Li Qiang Li xiao Li yang Li Jie liu Rong liu Shu-Bin liu xing-Yan liu Ze Long Guang-Yuan Luan Chang-Jun Ning meng-Chen Niu Bin-Bin Qi Jie Ren zhi-Zhou Ren xi-Chao Ruan Zhao-Hui Song Kang Sun zhi-Jia Sun zhi-xin Tan xin-Yi Tang Bin-Bin tian Li-Jiao wang Peng-Cheng wang Zhao-Hui wang zhong-wei Wen xiao-Guang wu Xuan wu Li-Kun xie xiao-Yun yang Yi-wei yang Han Yi Li Yu Tao Yu Yong-Ji Yu Guo-Hui Zhang Lin-Hao Zhang Qi-wei Zhang xian-Peng Zhang Yu-Liang Zhang zhi-Yong Zhang Lu-Ping Zhou zhi-Hao Zhou Ke-Jun Zhu 无 State Key Laboratory of Particle Detection and Electronics Institute of High Energy PhysicsChinese Academy of SciencesBeijing 100049China Department of Modern Physics University of Science and Technology of ChinaHefei 230026China Institute of Nuclear Physics and Chemistry China Academy of Engineering PhysicsMianyang 621900China Key Laboratory of Nuclear Data China Institute of Atomic EnergyBeijing 102413China Institute of High Energy Physics Chinese Academy of SciencesBeijing 100049China Spallation Neutron Source Science Center Dongguan 523803China State Key Laboratory of Nuclear Physics and Technology School of PhysicsPeking UniversityBeijing 100871China Northwest Institute of Nuclear Technology Xi’an 710024China University of Chinese Academy of Sciences Beijing 100049China Department of Engineering and Applied Physics University of Science and Technology of ChinaHefei 230026China State Key Laboratory of Particle Detection and Electronics University of Science and Technology of ChinaHefei 230026China The CSNS Back-n Collaboration

Back-streaming neutrons from the spallation target of the China Spallation Neutron Source(CSNS)that emit through the incoming proton channel were exploited to build a white neutron beam facility(the so-called Back-n white neutron source),which was completed in March *** Back-n neutron beam is very intense,at approximately 29107 n/cm2/s at 55 m from the target,and has a nominal proton beam with a power of 100 kW in the CSNS-I phase and a kinetic energy of 1.6 GeV and a thick tungsten target in multiple slices with modest moderation from the cooling water through the *** addition,the excellent energy spectrum spanning from 0.5 eV to 200 MeV,and a good time resolution related tothe time-of-flight measurements make it a typical white neutron source for nuclear data measurements;its overall performance is among that of the best white neutron sources in the *** with advanced spectrometers,detectors,and application utilities,the Back-n facility can serve wide applications,with a focus on neutron-induced cross-sectional *** article presents an overview of the neutron beam characteristics,the experimental setups,and the ongoing applications at Backn.

关键词： White neutron source Nuclear data measurements Experimental setups Neutron applications

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Anti-cyclic citrullinated peptide antibody predicts the development of rheumatoid arthritis in patients with undifferentiated arthritis

引用

Chinese Medical Journal 2019年第24期132卷 2899-2904页

作者： Chun Li Yan Zhang Hui Song Jie Gao Dong-Bao Zhao Qi Zhu Dong-Yi He Li wang xiang-Pei Li Xu-Dong liu wei-Guo xiao xin-Yu wu Hua-xiang wu wei Tu Shao-xian Hu xin wang zhi-Jun Li zhi-min Lu Zhan-Yun Da Bo Liang xiao-min liu Jin-wei Zhao Ling Li Feng Han wu-Fang Qi wei wei Xu Ma Zhen-Bin Li gui-min Zheng Feng-xiao Zhang Yi Li You-Lian wang Guang-Hui Ling Jin-wei Chen xiao-Qiang Hou Jing Zhang Qing-Ping Chen Chang-Lian liu Yan Zhang Jia-Shun Zeng Qing-Hua Zou Yong-Fei Fang Yin Su Zhan-Guo Li Department of Rheumatology and Immunology Peking University People's HospitalBeijing 100044China Department of Rheumatology and Immunology Beijing Jishuitan HospitalBeijing 100035China Department of Rheumatology and Immunology Changhai HospitalShanghai 200433China Department of Rheumatology Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western MedicineShanghai 200052China Department of Rheumatology and Immunology Anhui Provincial HospitalHefeiAnhui 230001China Department of Rheumatology and Immunology The First Hospital of China Medical UniversityShenyangLiaoning 110001China Department of Rheumatology The Second Affiliated Hospital of Zhejiang University School of MedicineHangzhouZhejiang 310009China Department of Rheumatology and Immunology Tongji HospitalWuhanHubei 430030China Department of Rheumatology The First Affiliated Hospital of Bengbu Medical CollegeBengbuAnhui 233004China Department of Rheumatology and Immunology Affiliated Hospital of Nantong UniversityNantongJiangsu 226001China Department of Rheumatology and Immunology The Hospital of Shunyi District BeijingBeijing 101300China Department of Infection and Immunology Tianjin Union Medical CenterTianjin 300121China Department of Rheumatology and Immunology Tianjin First Central HospitalTianjin 300192China Department of Rheumatology and Immunology Tianjin Medical University General HospitalTianjin 300052China Department of Rheumatology and Immunology Peace HospitalShijiazhuangHebei 050000China Department of Rheumatology and Immunology Hebei General HospitalShijiazhuangHebei 050051China Department of Rheumatology Jiangxi Provincial People's HospitalNanchangJiangxi 330006China Division of Rheumatology and Immunology The Second Xiangya Hospital of Central South UniversityChangshaHunan 410011China Department of Rheumatology and Immunology The First College of Clinical Medical Science of China Three Gorges University&Yichang Central People's HospitalYichangHubei 443003China Department of Rheu

Background:Clinical outcomes of undifferentiated arthritis(UA)are diverse,and only 40%of patients with UA develop rheumatoid arthritis(RA)after 3 *** predictive markers at disease onset for further intervention is ***,our objective was to analyze the clinical outcomes of UA and ascertain the predictors for RA ***:We performed a prospective,multi-center study from January 2013 to October 2016 among Chinese patients diagnosed with UA in 22 tertiary-care *** and serological parameters were obtained at ***-up was undertaken in all patients every 12 weeks for 2 *** factors of disease progression were identified using multivariate Cox proportional hazards ***:A total of 234 patients were recruited in this study,and 17(7.3%)patients failed to follow up during the *** the 217 patients who completed the study,83(38.2%)patients went into *** patients who developed RA had a higher rheumatoid factor(RF)-positivity(42.9%vs.16.8%,χ^2=8.228,P=0.008),anti-cyclic citrullinated peptide(CCP)antibodypositivity(66.7%vs.10.7%,χ^2=43.897,P<0.001),and double-positivity rate of RF and anti-CCP antibody(38.1%vs.4.1%,χ^2=32.131,P<0.001)than those who did ***-CCP antibody but not RF was an independent predictor for RA development(hazard ratio 18.017,95%confidence interval:5.803–55.938;P<0.001).Conclusion:As an independent predictor of RA,anti-CCP antibody should be tested at disease onset in all patients with UA.

关键词： Anti-cyclic citrullinated peptide antibody Arthritis,Rheumatoid Rheumatoid factor Undifferentiated arthritis

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Inverted U-Shaped Associations between Glycemic Indices and Serum Uric Acid Levels in the General Chinese Population:Findings from the China Cardiometabolic Disease and Cancer Cohort(4C)Study

引用

Biomedical and Environmental Sciences 2021年第1期34卷 9-18页

作者： ZHU Yuan Yue ZHENG Rui zhi wang gui xia CHEN Li SHI Li xin SU Qing XU min XU Yu CHEN Yu Hong YU Xue Feng YAN Li wang tian Ge ZHAO zhi Yun QIN gui Jun WAN Qin CHEN Gang GAO Zheng Nan SHEN Fei xia LUO Zuo Jie QIN Ying Fen HUO Ya Nan LI Qiang YE Zhen ZHANG Yin Fei liu Chao wang You min wu Sheng Li yang Tao DENG Hua Cong ZHAO Jia Jun CHEN Lu Lu MU Yi ming TANG Xu Lei HU Ru Ying wang wei Qing NING Guang LI Mian LU Jie Li BI Yu Fang Department of Endocrine and Metabolic Diseases Shanghai Institute of Endocrine and Metabolic DiseasesRuijin HospitalShanghai Jiao Tong University School of MedicineShanghai 200025China Shanghai National Clinical Research Center for Metabolic Diseases Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR ChinaShanghai National Center for Translational MedicineRuijin Hospital.Shanghai Jiao Tong UniversitySchool of MedicineShanghai 200025China The First Hospital of Jilin University Changchun 130021JinlinChina Qilu Hospital of Shandong University Jinan 250012ShandongChina Affiliated Hospital of guiyang Medical College Guiyang 550004GuizhouChina xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine Shanghai 200092China Tongji Hospital.Tongji Medical College Huazhong University of Science and TechnologyWuhan 430030HubeiChina Sun Yat-sen Memorial Hospital Sun Yat-sen UniversityGuangzhou 510120GuangdongChina The First Affiliated Hospital of Zhengzhou University Zhengzhou 450052HenanChina The Affiliated Hospital of Southwest Medical University Luzhou 646099SichuanChina Fujian Provincial Hospital Fujian Medical UniversityFuzhou 350001FujianChina Dalian Municipal Central Hospital Dalian 116003LiaoningChina The First Affiliated Hospital of Wenzhou Medical University Wenzhou 325000ZhejiangChina The First Affiliated Hospital of Guangxi Medical University Nanning 530021GuangxiChina Jiangxi Provincial People's Hospital Affiliated to Nanchang University Nanchang 330006JiangxiChina The Second Affiliated Hospital of Harbin Medical University Harbin 150086HeilongjiangChina Zhejiang Provincial Center for Disease Control and Prevention Hangzhou 310051ZhejiangChina Central Hospital of Shanghai Jiading District Shanghai 201800China Jiangsu Province Hospital on Integration of Chinese and Western Medicine Nanjing 210028JiangsuChina The First Affiliated Hospital of Anhui Medical University Hefei 230022AnhuiChina Karamay Municipal

Objective The relationship between serum uric acid(SUA)levels and glycemic indices,including plasma glucose(FPG),2-hour postload glucose(2 h-PG),and glycated hemoglobin(HbA1 c),remains *** aimed to explore the associations between glycemic indices and SUA levels in the general Chinese *** The current study was a cross-sectional analysis using the first follow-up survey data from The China Cardiometabolic Disease and Cancer Cohort Study.A total of 105,922 community-dwelling adults aged≥40 years underwent the oral glucose tolerance test and uric acid *** nonlinear relationships between glycemic indices and SUA levels were explored using generalized additive *** A total of 30,941 men and 62,361 women were eligible for the current *** additive models verified the inverted U-shaped association between glycemic indices and SUA levels,but with different inflection points in men and *** thresholds for FPG,2 h-PG,and HbA1 c for men and women were 6.5/8.0 mmol/L,11.0/14.0 mmol/L,and 6.1/6.5,respectively(SUA levels increased with increasing glycemic indices before the inflection points and then eventually decreased with further increases in the glycemic indices).Conclusion An inverted U-shaped association was observed between major glycemic indices and uric acid levels in both sexes,while the inflection points were reached earlier in men than in women.

关键词： Cross-sectional study Serum uric acid Glycemic index Glycemic status

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Prevalence, awareness, treatment, and control of hypertension in the non-dialysis chronic kidney disease patients

引用

Chinese Medical Journal 2013年第12期126卷 2276-2280页

作者： ZHENG Ying CAI Guang-yan CHEN xiang-mei FU Ping CHEN Jiang-hua DING xiao-qiang YU Xue-qing LIN Hong-li liu Jian xiE Ru-juan wang Li-ning NI Zhao-hui liu Fu-you YIN Ai-ping xiNG Chang-ying wang Li SHI wei liu Jian-she HE Ya-ni DING Guo-hua LI Wen-ge wu Guang-li MIAO Li-ning CHEN Nan SU Zhen MEI Chang-lin ZHAO Jiu-yang GU Yong BAI Yun-kai LUO Hui-min LIN Shan CHEN meng-hua GONG Li yang Yi-bin yang xiao-ping LI Ying WAN Jian-xin wang Nian-song LI Hai-ying xi Chun-sheng HAO Li XU Yan FANG Jing-ai liu Bi-cheng LI Rong-shan wang Rong ZHANG Jing-hong wang Jian-qin LOU Tan-qi SHAO Feng-min MEI Feng liu zhi-hong YUAN wei-jie SUN Shi-ren ZHANG Ling ZHOU Chun-hua CHEN Qin-kai JIA Shun-lian GONG zhi-feng GUAN Guang-ju xiA tian zhong Liang-bao Department of Nephrology State key Laboratory of Kidney Disease Chinese PLA General Hospital Beijing 100853 China Nephrology Institute of the Chinese People's Liberation Army Chinese People's Liberation Army Key Laboratory of Nephrology Beijing 100853 China Department of Nephrology West China Hospital of Sichuan University Chengdu Sichuan 610041 China Department of Nephrology First Affiliated Hospital School of Medicine Zhejiang University Hangzhou Zhejiang 310003 China Department of Nephrology Zhongshan Hospital Fudan University Shanghai 200032 China Department of Nephrology First Affiiated Hospital of Sun Yat-sen University Guangzhou Guangdong 510080 China Department of Nephrology First Affiliated Hospital of Dalian Medical University Dalian Liaoning 116011 China Department of Nephrology First Affiliated Hospital of Xinjiang Medical University Urumqi Xinjiang 830054 China Department of Nephrology First Affiliated Hospital of Harbin Medical University Harbin Heilongjiang 150001 China Department of Nephrology First Afftiated Hospital of China Medical University Shenyang Liaoning 110001 China Department of Nephrology Renji Hospital School of Medicine Shanghai Jiao Tong University Shanghai 200025 China Department of Nephrology Second Xiangya Hospital Central South University Changsha Hunan 410000 China Department of Nephrology First Affiliated Hospital of Medical College Xi'an Jiaotong University Xi'an Shaanxi 710061 China Department of Nephrology First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital) Nanjing Jiangsu 210029 China Department of Nephrology Sichuan Provincial People's Hospital Chengdu Sichuan 610072 China Department of Nephrology Guangdong Provincial People's Hospital Guangzhou Guangdong 510030 China Department of Nephrology Affliated Xiehe Hospital Tongji Medical College Huazhong Science and Technology University Wuhan Hubei 430022 China Department of Nephrology Daping Hospital Third Military Medi

Background Data on the epidemiology of hypertension in Chinese non-dialysis chronic kidney disease （CKD） patients are *** aim of the present study was to investigate the prevalence,awareness,treatment,and control of hypertension in the non-dialysis CKD patients through a nationwide,multicenter study in *** The survey was performed in 61 tertiary hospitals in 31 provinces,municipalities,and autonomous regions in China （except Hong Kong,Macao,and Taiwan）.Trained physicians collected demographic and clinical data and measured blood pressure （BP） using a standardized *** was defned as systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg,and/or use of antihypertensive *** 〈140/90 mmHg and 〈130/80 mmHg were used as the 2 thresholds of hypertension *** multivariate logistic regression with adjustment for sex and age,we analyzed the association between CKD stages and uncontrolled hypertension in non-dialysis CKD *** The analysis included 8927 non-dialysis CKD *** prevalence,awareness,and treatment of hypertension in non-dialysis CKD patients were 67.3%,85.8%,and 81.0%,*** hypertensive CKD patients,33.1% and 14.1% had controlled BP to 〈140/90 mmHg and 〈130/80 mmHg,*** successive CKD stages,the prevalence of hypertension in non-dialysis CKD patients increased,but the control of hypertension decreased （P〈0.001）.When the threshold of BP 〈130/80 mmHg was considered,the risk of uncontrolled hypertension in CKD 2,3a,3b,4,and 5 stages increased 1.3,1.4,1.4,2.5,and 4.0 times compared with CKD 1 stage,respectively （P〈0.05）.Using the threshold of 〈140/90 mmHg,the risk of uncontrolled hypertension increased in advanced stages （P〈0.05）.Conclusions The prevalence of hypertension Chinese non-dialysis CKD patients was high,and the hypertension control was *** successive CKD stages,the risk of uncontrolled hypertension increased.

关键词： non-dialysis chronic kidney disease chronic kidney disease stages hypertension epidemiology

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma:A single-arm, multicenter, prospective study

引用

Hepatobiliary & Pancreatic Diseases International 2022年第2期21卷 106-112页

作者： Ren-Yi Su Sun-Bin Ling Qiao-Nan Shan Xu-Yong wei Rui wang Chang-Ku Jia Li Zhuang tian Shen Li-min Ding zhi-Dan Xu Lai-Bang Luo Li-Bo Sun Guang-ming Li Tai-Shi Fang Nan Jiang Kun Zhang Zhao-Jie Su zhi-Hai Peng Ren Lang Tao Jiang Qiang He Lin-Sen Ye yang yang Yu-Ting He Wen-zhi Guo liu-Gen Lan Xu-Yong Sun Dong Chen zhi-Shui Chen Da-wei Zhou Shao-Jun Ye Qi-Fa Ye min tian Jian-Hua Shi Bo wang Jiang liu Qian Lu wei Rao Jin-Zhen Cai Tao Lv Jia-Yin yang Pu-Sen wang Lin zhong Jing-Sheng Ma Qi-Gen Li Sheng-Dong wu Chang-Jiang Lu Cai-De Lu Dong-Hua Zhang Xuan wang Zi-Qiang Li Mu-Jian Teng Jun-Jie Li Wen-Tao Jiang Jian-Hua Li Quan-Bao Zhang Ning-Qi Zhu Zheng-xin wang Kang He Qiang xia Shao-Hua Song zhi-Ren Fu wei Qiu Guo-Yue Lv Rui-Peng Song Ji-Zhou wang Zheng wang Jian Zhou Gang Chen Ying-Peng Zhao Li Li Ze-min Hu Qi-Jie Luo zhong-Zhou Si Bin xie xiao-Shun He zhi-Yong Guo Shu-Sen Zheng xiao Xu Department of Hepatobiliary and Pancreatic Surgery The Center for Integrated Oncology and Precision MedicineAffiliated Hangzhou First People’s HospitalZhejiang University School of MedicineHangzhou 310006China NHC Key Laboratory of Combined Multi-organ Transplantation Hangzhou 310003China Department of Hepatobiliary and Pancreatic Surgery Shulan(Hangzhou)HospitalZhejiang Shuren University School of MedicineHangzhou 310022China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Transplantation Jiangxi Provincial People’s Hospital Affiliated to Nanchang UniversityNanchang 330006China Liver Transplantation Center Beijing You’an HospitalCapital Medical UniversityBeijing 100069China Department of Hepatic Surgery National Clinical Research Center for Infectious DiseaseShenzhen Third People’s HospitalThe Second Affiliated Hospital of Southern University of Science and TechnologyShenzhen 518112China Department of General Surgery Xiang’an Hospital of Xiamen UniversityXiamen 361000China Deartment of Hepatobiliary and Pancreaticosplenic Surgery Beijing Chaoyang HospitalCapital Medical UniversityBeijing 100020China Department of Hepatic Surgery and Liver Transplantation Center The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510630China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China Department of Liver Transplantation The Second Affiliated Hospital of Guangxi Medical UniversityNanning 530000China Institute of Organ Transplantation Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Institute of Hepatobiliary Diseases of wuhan University Transplant Center of Wuhan UniversityHubei Key Laboratory of Medical Technology on TransplantationZhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Hepatobiliary Surgery The First Affiliated Hos

Mammalian target of rapamycin(m TOR) inhibitor as an attractive drug target with promising antitumor effects has been widely investigated. High quality clinical trial has been conducted in liver transplant(LT) recipients in Western countries. However, the pertinent studies in Eastern world are paucity. Therefore, we designed a clinical trial to test whether sirolimus can improve recurrence-free survival(RFS) in hepatocellular carcinoma(HCC) patients beyond the Milan criteria after LT. This is an open-labeled, single-arm, prospective, multicenter, and real-world study aiming to evaluate the clinical outcomes of early switch to sirolimus-based regimens in HCC patients after LT. Patients with a histologically proven HCC and beyond the Milan criteria will be enrolled. The initial immunosuppressant regimens are center-specifc for the frst 4-6 weeks. The following regimens integrated sirolimus into the regimens as a combination therapy with reduced calcineurin inhibitors based on the condition of patients and centers. The study is planned for 4 years in total with a 2-year enrollment period and a 2-year follow-up. We predict that sirolimus conversion regimen will provide survival benefts for patients particular in the key indicator RFS as well as better quality of life. If the trial is conducted successfully, we will have a continued monitoring over a longer follow-up time to estimate indicator of overall survival. We hope that the outcome will provide better evidence for clinical decision-making and revising treatment guidelines based on Chinese population data.

关键词： Sirolimus Immunosuppressive agents Hepatocellular carcinoma Liver transplantation Conversion

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

A randomized, multicenter controlled trial to compare the efficacy of recombinant human parathyroid hormone （1-34） with elcatonin in postmenopausal women with osteoporosis in China

引用

Chinese Medical Journal 2009年第24期122卷 2933-2938页

作者： ZHANG xiu-zhen wang Bo yang Jun XUAN Miao SONG Li-ge LI Hong GUO xiao-hui LU xiao-feng XUE Qing-yun yang Gang-yi JI Qiu-he SHEN Jie liu zhi-min LI Cheng-jiang wu tian-feng TONG xiao-cui JIA Yuan Department of Endocrinology Tongji Hospital of Tongji University Shanghai 200065 China Department of Endocrinology Peking University First Hospital Beijing 100034 China Department of Endocrinology General Hospital of the Chinese People's Liberation Army Beijing Military Region Beijing 100700 China Department of Endocrinology Beijing Hospital Beijing 100730 China Department of Endocrinology Second Affiliated Hospital of Chongqing Medical University Chongqing 400010 China Department of Endocrinology Xijing Hospital of Fourth Military Medical University Xi'an Shaanxi 710032 China Department of Endocrinology Nanfang Hospital of Nanfang Medical University Guangzhou Guangdong 510515 China Department of Endocrinology Changzheng Hospital Second Military Medical University Shanghai 200003 China Department of Endocrinology First Affiliated Hospital of Zhejiang University Hangzhou Zhejiang 310003 China Department of Endocrinology Zhejiang Hospital Hangzhou Zhejiang 310013 China

Background Recombinant human parathyroid hormone （1-34）（rhPTH （1-34）） given by injection is a new seventh class drug of biological products, which is prepared by adopting gene recombination technique, rhPTH （1-34） is mainly used to treat osteoporosis, especially for postmenopausal women. This study compared the clinical efficacy and safety of rhPTH （1-34） with elcatonin for treating postmenopausal women with osteoporosis in 11 urban areas of China. Methods Two hundred and five women with osteoporosis were enrolled in a 6-month, multicenter, randomized, controlled study. They were randomized to receive either rhPTH （1-34） 20 ug （200 U） daily or elcatonin 20 U weekly. Lumbar spine （L1-4） and femoral neck bone mineral density （BMD）, as well as biochemical markers of bone turnover were measured. Adverse events were recorded. Results rhPTH （1-34） increased lumbar BMD significantly more than did elcatonin at 3 months and 6 months （2.38% vs 0.59%, P 〈0.05; 5.51% vs 1.55%, P 〈0.01）, but there were no significant increases of BMD in these two groups at femoral neck. There were larger mean increases in bone markers in the rhPTH （1-34） group than in the elcatonin group at 3 months and 6 months （serum bone-specific alkaline phosphatase （BSAP） 36.79% vs 0.31%; 92.42% vs -0.17%; urinary N-telopeptide/creatinine （NTX/Cr） 48.91% vs -5.32%; 68.82% vs -10.86%）. Both treatments were well tolerated and there were no significant differences detected between the two groups in the proportion of any adverse events and any serious adverse events （67.0% vs 59.0%; 0 vs 0）. Conclusions rhPTH （1-34） has more positive effects on bone formation, as shown by the larger increments of lumbar BMD and bone formation markers, than elcatonin, with only mild adverse events and no significant change in the liver, kidney or hematological indices.

关键词： recombinant human parathyroid hormone elcatonin osteoporosis bone mineral density

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Comparison of parathyroid hormone （1-34） and elcatonin in postmenopausal women with osteoporosis： an 18-month randomized, multicenter controlled trial in China

引用

Chinese Medical Journal 2013年第3期126卷 457-463页

作者： LI Ying XUAN Miao wang Bo yang Jun ZHANG Hong ZHANG xiu-zhen GUO xiao-hui Lü xiao-feng XUE Qing-yun yang Gang-yi JI Qiu-he liu zhi-min LI Cheng-jiang wu tian-feng SHENG Zheng-yan LI Peng-qiu TONG Jiu-cui Department of Endocrinology Tongji Hospital of Tongji University Shanghai 200065 China Department of Endocrinology Peking University First Hospital Beijing 100034 China Department of Endocrinology General Hospital of Chinese People's Liberation Army Beijing Military Region Beijing 100700 China Department of'Endocrinology Beijing Hospital Beijing 100730 China Department of Endocrinology Second Affiliated Hospital of Chongqing Medical University Chongqing 400010 China Department of Endocrinology Xijing Hospital of Fourth Military Medical University Xi'an Shaanxi 710032 China Department of Endocrinology Changzheng Hospital Second Military Medical University Shanghai 200003 China Department of Endocrinology First Affiliated Hospital of Zhejiang University Hangzhou Zhejiang 310003 China Department of Endocrinology Zhejiang' Hospital Hangzhou Zhejiang 310013 China Department of Endocrinology Shanghai First People's Hospital Shanghai 200080 China Department of Endocrinology Sichuan Provicial People's Hospital Chengdu Sichuan 610072 China Anhui Provincial Center for Clinical Evaluation of Drug Wuhu Anhui 241001 China

Background Recombinant human parathyroid hormone （1-34）（rhPTH （1-34）） is the first agent in a unique class of anabolic therapies acting on the skeleton. The efficacy and safety of long-term administration of rhPTH （1-34） in Chinese postmenopausal women had not been evaluated. This study compared the clinical efficacy and safety of rhPTH （1-34） with elcatonin for treating postmenopausal women with osteoporosis in 11 urban areas of China. Methods A total of 453 postmenopausal women with osteoporosis were enrolled in an 18-month, multi-center, randomized, controlled study. They were randomized to receive either rhPTH （1-34） 20 μg （200 U） daily for 18 months, or elcatonin 20 U weekly for 12 months. Lumbar spine （L1-4） and femoral neck bone mineral density （BMD）, fracture rate, back pain as well as biochemical markers of bone turnover were measured. Adverse events were recorded. Results rhPTH （1-34） increased lumbar BMD significantly more than did elcatonin after 6, 12, and 18 months of treatment （4.3% vs. 1.9%, 6.8% vs. 2.7%, 9.5% vs. 2.9%, P 〈0.01）. There was only a small but significant increase of femoral neck BMD after 18 months （2.6%, P 〈0.01） in rhPTH groups. There were larger increases in bone turnover markers in the rhPTH （1-34） group than those in the elcatonin group after 6, 12, and 18 months （serum bone-specific alkaline phosphatase （BSAP） 93.7% vs. -3.6%; 117.8% vs. -4.1%; 49.2% vs. -5.8%, P 〈0.01; urinary C-telopeptide/creatinine （CTX/Cr） 250.0% vs. -29.5%; 330.0% vs. -41.4%, 273.0% vs. -10.6%, P 〈0.01）. rhPTH （1-34） showed similar effect of pain relief as elcatonin. The incidence of clinical fractures was 5.36% （6/112） in elcatonin group and 3.2% （11/341）in rhPTH （1-34）group （P=0.303）. Both treatments were well tolerated. Hypercaluria （9.4%） and hypercalcemia （7.0%） in rhPTH （1-34） group were transient and caused no clinical symptoms. Pruritus （8.2% vs. 2.7%, P=0.044） and redness of injection site （4.4% vs. 0,P=0.024） were more frequent in rhPTH （1-34）. N

关键词： recombinant human parathyroid hormone elcatonin osteoporosis bone mineral density fraeture

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Validation of the chinese version of the EORTC QLQ-CR29 in patients with colorectal cancer

引用

World Journal of Gastroenterology 2017年第10期23卷 1891-1898页

作者： Jin-bo Lin Lei Zhang Dong-Wen wu Zhou-Huan xi xue-Jun wang Yun-Shou Lin Wakana Fujiwara Jing-Ru tian min wang Peng Peng Ai Guo Zhen yang Le Luo Ling-Ya Jiang Qia-Qia Li xue-Ying Zhang Yun-Feng Zhang Hou-wei xu bing yang xun-Lin Li Yi-xiong Lei School of Public Health Guangzhou Medical University Longgang Central Hospital of Shenzhen Department of Thoracic Surgery Tianjin Medical University Cancer Institute and HospitalNational Clinical Research Center for CancerKey Laboratory of Cancer Prevention and TherapyTianjin Lung Cancer Center xiangya School of Medicine Central South University Department of Gastrointestinal Surgery Tianjin Medical University Cancer Institute and HospitalNational Clinical Research Center for CancerKey Laboratory of Cancer Prevention and TherapyTianjin Lung Cancer Center tianjin Medical University School of Medicine Georgetown University Department of Radiation Oncology Tumor HospitalXiangya School of Medicine of Central South University Longgang District Peoples Hospital of Shenzhen1 Cancer Center of Guangzhou Medical University

AIM To assess the validity and reliability of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Colorectal Cancer 29 (EORTC QLQ-CR29) in Chinese patients with colorectal cancer (CRC). METHODS From March 2014 to January 2015, 356 patients with CRC from four different hospitals in China were enrolled in the study, and all patients self-administered the EORTC QLQ-CR29 and the quality of life core questionnaire (EORTC QLQ-C30). Evaluation of the scores was based on the Karnofsky Performance Scale (KPS). The reliability and validity of the questionnaires were assessed by Cronbach's proportional to coefficient, the Spearman correlation test and Wilcoxon rank sum test. RESULTS The EORTC QLQ-CR29 showed satisfactory reliability (proportional to > 0.7), although the urinary frequency and blood and mucus in stool dimensions had only moderate reliability (proportional to = 0.608). The multitrait scaling analyses showed good convergent (r > 0.4) and discriminant validity. Significant differences were obtained for each item in the different KPS subgroups (KPS 80). Body image and most single- item dimensions showed statistically significant differences in patients with a stoma compared with the rest of the patients. CONCLUSION The EORTC QLQ-CR29 exhibits high validity and reliability in Chinese patients with CRC, and can therefore be recommended as a valuable tool for the assessment of quality of life in these patients.

关键词： Colorectal cancer Health-related quality of life EORTC QLQ-CR29 China's Mainland

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：